A directory of where to buy chemicals in the USA, including: distributors, industrial manufacturers, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the suppliers website for prices or more information.
| Product | Description | |
|---|---|---|
| GS-7340 fumarate | Tenofovir alafenamide fumarate, also known as Tenofovir alafenamide hemifumarate; TAF, GS-7340, is a nucleotide reverse transcriptase inhibitor and a novel prodrug of tenofovir. It is under development by Gilead Sciences for use in the treatment of HIV infection. Closely related to the commonly used reverse-transcriptase inhibitor tenofovir disoproxil fumarate (Viread), Tenofovir alafenamide has greater antiviral activity and better distribution into lymphoid tissues than that agent. Gilead has announced a phase 3 clinical trial evaluating a single-tablet regimen combining GS-7340 with cobicistat, emtricitabine and elvitegravir and plans to coformulate the drug with cobicistat, emtricitabine and the protease inhibitor darunavir. In a 48 week study comparing Elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil fumarate to elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide fumarate, the results showed the prodrug to be non inferior to the established agent, but at much lower dosages and with lower incidence of adverse side effects such as impaired kidney function. Synonyms: GS-7340 fumarate; GS 7340 fumarate; GS7340 fumarate; (S)-isopropyl 2- ( ( (S)- ( ( ( (R)-1- (6-amino-9H-purin-9-yl)propan-2-yl)oxy)methyl) (phenoxy)phosphoryl)amino)propanoate fumarate; TAF; GS734; GS-734; GS 7340; Tenofovir alafenamide fumarate; trade name: Genvoya. Grades: >98%. CAS No. 379270-38-9. Molecular formula: C25H33N6O9P. Mole weight: 592.54. |  |
| GS87 | ?95% (HPLC). Group: Fluorescence/luminescence spectroscopy. |  |
| GS-9219 | GS-9219 is a prodrug of the acyclic nucleoside phosphonate analogue 9-(2-phosphonylmethoxyethyl)guanine (PMEG) with potential antineoplastic activity. Formulated to selectively accumulate in lymphocytes, nucleotide analogue GS 9219 is converted to its active metabolite, PMEG diphosphate (PMEGpp), via enzymatic hydrolysis, deamination, and phosphorylation; subsequently, PMEGpp is incorporated into nascent DNA chains by DNA polymerases, which may result in the termination of DNA synthesis, S-phase cell cycle arrest, and the induction of apoptosis in susceptible lymphoma cell populations. Synonyms: GS 9219; GS9219. CAS No. 859209-74-8. Molecular formula: C21H35N8O6P. Mole weight: 526.53. | |
| GS 9620 | GS 9620 is a potent and oral agonist of TLR7. Uses: Antiviral agents. Synonyms: 4-amino-2-butoxy-8-[[3-(pyrrolidin-1-ylmethyl)phenyl]methyl]-5,7-dihydropteridin-6-one; GS-9620; GS9620; Vesatolimod. Grades: 99.90%. CAS No. 1228585-88-3. Molecular formula: C22H30N6O2. Mole weight: 410.51. | |
| GS9667 | GS9667 is a new selective, partial agonist of the A(1) adenosine receptor (AR). It may be an effective therapy for Type 2 diabetes and dyslipidemia via lowering of free fatty acids (FFA). It was developed by Gilead and was in clinic phase 1 trials without progress. Uses: Gs966 may be an effective therapy for type 2 diabetes and dyslipidemia via lowering of free fatty acids (ffa). Synonyms: GS-9667; GS 9667; CVT-3619; CVT 3619; CVT3619. Grades: 98%. CAS No. 618380-90-8. Molecular formula: C21H24FN5O4S. Mole weight: 461.51. | |
| GS-9667 | GS-9667 (CVT 3619), a novel N 6 -5'-substituted adenosine analog, is a selective, partial agonist of the A 1 adenosine receptor (A 1 AdoR). GS-9667 binds to adipocyte membranes with high (K H =14 nM) and low (K L =5.4 μM) affinities. GS-9667 reduces cyclic AMP content and release of nonesterified fatty acids from epididymal adipocytes with IC 50 values of 6 nM and 44 nM, respectively. GS-9667 inhibits lipolysis and has the potential for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA) [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CVT 3619. CAS No. 618380-90-8. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19842. |  |
| GS967 | GS967, also known as GS-458967, is a highly selective late sodium channel current blocker. The selective inhibition of late INa with GS967 can exert antiarrhythmic effects by suppressing EAD- and DAD-mediated extrasystolic activity in PFs and PV and SVC sleeve preparations. Synonyms: GS967; GS-967; GS 967; GS458967; GS 458967; GS-458967. Grades: 98%. CAS No. 1262618-39-2. Molecular formula: C14H7F6N3O. Mole weight: 347.22. | |
| GS-9822 | GS-9822 is one of novel non-catalytic site integrase inhibitors (NCINIs), which is a potential class of antiretroviral (ARV) agents. GS-9822 exhibits a potent effect against the T174I mutant (EC50: 3.0 ± 0.9 nM) and IN polymorphic variants (fold shift: 0.4 to 1.3). Studies showed that it has excellent pharmacokinetic properties and metabolic stability. Uses: Antiretroviral (arv) agent. Synonyms: GS 9822; GS9822. CAS No. 2219362-41-9. Molecular formula: C36H39ClN4O4S. Mole weight: 659.24. | |
| GSA 10 | GSA 10. Group: Biochemicals. Grades: Purified. CAS No. 300833-95-8. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. |  Worldwide |
| GSA 10 | GSA 10 is a quinolinecarboxamide derivative that acts as a Smoothened/Smo receptor agonist (EC50 = 1.2 μM). GSA 10 can promote differentiation of multipotent mesenchymal progenitor cells into osteoblasts. Uses: Smoothened (smo) receptor agonist. Synonyms: GSA-10; propyl 4-[(1-hexyl-4-hydroxy-2-oxoquinoline-3-carbonyl)amino]benzoate. Grades: >98%. CAS No. 300833-95-8. Molecular formula: C26H30N2O5. Mole weight: 450.53. | |
| GSA-10 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| Gsa I | One unit of the enzyme is the amount required to hydrolyze 1 μg of Lambda DNA in 1 hour at 70°C in a total reaction volume of 50 μl. Applications: After 20-fold overdigestion with enzyme about 90% of the dna fragments can be ligated and recut. Group: Restriction Enzymes. Purity: 1000U; 5000U. CCCAG↑C G↓GGTCG. Activity: 10000-20000u.a./ml. Appearance: 10 X SE-buffer W, BSA. Storage: -20°C. Form: Liquid. Source: Geobacillus stearothermophilus Y. Pack: 10 mM Tris-HCl (pH 7.5); 100 mM NaCl; 0,1 mM EDTA; 7 mM 2-mercaptoethanol; 200 μg/ml BSA; 50% glycerol. Cat No: ET-1115RE. |  |
| GS-CA-1 | GS-CA-1 is a novel HIV capsid inhibitor developed by Gilead, which is a promisingly long-acting antiretroviral (ARV) agent. The preclinical study showed that GS-CA-1 could inhibit HIV-1 replication in human peripheral blood mononuclear cells (PBMCs) (EC50 = 140 pM). Uses: Long-acting antiretroviral (arv) agent. Synonyms: GS CA 1. Grades: 99.94%. CAS No. 2189684-45-3. Molecular formula: C41H36ClF8N7O5S2. Mole weight: 958.34. | |
| g-Secretase Inhibitor XX ( (S, S) -2-[2- (3, 5-Difluorophenyl) acetylamino]-N- (5-methyl-6-oxo-6, 7-dihydro-5H-dibenzo[b, d]azepin-7-yl) propionamide, DBZ, Dibenzazepine) | A cell-permeable dibenzazepine (dbz) compound that acts as a potent y-secretase inhibitor and significantly lowers both brain and plasma AB40 levels by ~72% in Tg2576 mutant APP transgenic mouse model (100umol/kg, b.i.d). Induces a heterogeneous reorganization of the crypt structural-proliferative units in the intestinal tract and of the stem cell niche in the colon. Also potently inhibits Notch processing (IC50=1.7nM in SupT1 cells) and induces conversion of proliferative crypt cells to post-mitotic goblet cells in both the C57BL/6 and ApcMin mouse models (10umol/kg, i.p). CAS Number:209984-56-5. Group: Biochemicals. Grades: Highly Purified. CAS No. 209984-56-5. Pack Sizes: 500ug, 1mg. US Biological Life Sciences. | Worldwide |
| GSG2 (470-end), active, GST tagged human | recombinant, expressed in baculovirus infected Sf9 cells, ?70% (SDS-PAGE), buffered aqueous glycerol solution. Group: Fluorescence/luminescence spectroscopy. | |
| GSH-CdTe, | GSH-CdTe. Group: Quantum dots. |  |
| GSI-136 | GSI-136 is an amyloid precursor protein secretase inhibitor. Uses: γ-secretase inhibitor. Synonyms: GSI-136; GSI 136; GSI136. (S)-5-chloro-N-(3-ethyl-1-hydroxypentan-2-yl)thiophene-2-sulfonamide. Grades: ≥98%. CAS No. 443989-01-3. Molecular formula: C11H18ClNO3S2. Mole weight: 311.83. | |
| GSI-953 | Begacestat (GSI-953) is a selective β-secretase inhibitor that selectively inhibits cleavage of APP over Notch. GSI-953 is used for treating diseases such as cancer in relation to prevention of intestinal secretory metaplasia. Group: Biochemicals. Alternative Names: 5-Chloro-N-[ (1S) -3, 3, 3-trifluoro-1- (hydroxymethyl) -2- (trifluoromethyl) propyl]-2-thiophenesulfonamide; Begacestat; GSI 953. Grades: Highly Purified. CAS No. 769169-27-9. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| GSK046 | GSK046 (iBET-BD2) is a potent, selective and orally active BD2 bromodomain inhibitor of the BET proteins, with IC50s of 264 nM (BRD2 BD2), 98 nM (BRD3 BD2), 49 nM (BRD4 BD2) and 214 nM (BRDT BD2), respectively. GSK046 has immunomodulatory activity[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: iBET-BD2. CAS No. 2474876-09-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-136571. | |
| GSK0660 | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK0660 | GSK0660 is a selective PPARδ antagonist. GSK0660 blocks the effect of TNFα on the expressions of cytokines involved in leukocyte recruitment, including CCL8, CCL17, and CXCL10, and it may block TNFα-induced retinal leukostasis. Synonyms: GSK0660; GSK-0660; GSK 0660. Grades: 96%. CAS No. 1014691-61-2. Molecular formula: C19H18N2O5S2. Mole weight: 418.48. | |
| GSK0660 | GSK0660 is a potent PPAR? antagonist with an IC50 of 155 nM. Uses: Scientific research. Group: Signaling pathways. CAS No. 1014691-61-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-12377. | |
| GSK 0660 | GSK 0660. Group: Biochemicals. Grades: Purified. CAS No. 1014691-61-2. Pack Sizes: 10mg, 50mg. US Biological Life Sciences. | Worldwide |
| GSK-1014802 hydrochloride | GSK-1014802 hydrochloride is the hydrochloride form of GSK-1014802, which is a novel analgesic for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia. It acts as a selective, small-molecule, state-dependent Nav1.7 voltage-gated sodium channel blocker. It received orphan-drug designation from the US Food and Drug Administration in July 2013. It was developed by Convergence Pharmaceuticals. It is currently in phase II studies in bipolar depression. Uses: Gsk-1014802 hydrochloride is a novel analgesic for the treatment of lumbosacral radiculopathy (sciatica) and trigeminal neuralgia. it received orphan-drug designation from the us food and drug administration in july 2013. Synonyms: GSK-1014802 hydrochloride; GSK 1014802 hydrochloride; GSK1014802 hydrochloride; (2S,5R)-5-(4-((2-Fluorobenzyl)oxy)phenyl)pyrrolidine-2-carboxamide hydrochloride;(5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-L-prolinamide hydrochlorideCNV1014802 hydrochloride;CNV-1014802 hydrochloride;Raxatrigine hydrochloride. Grades: >98%. CAS No. 934240-31-0. Molecular formula: C18H20ClFN2O2. Mole weight: 350.82. | |
| GSK1016790A | GSK1016790A is a potent and selective transient receptor potential vanilloid 4 (TRPV4) channel agonist. GSK1016790A can elicit Ca2+ influx and elevate intracellular Ca2+ in HEK cells[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 942206-85-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19608. | |
| GSK1016790A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK1016790A | GSK1016790A is a novel and potent TRPV4 channel agonist. The TRPV4 (transient receptor potential vanilloid 4) member of the TRP superfamily has been implicated in numerous physiological processes. GSK1016790A elicited Ca2+ influx in mouse and human TRPV4 expressing HEK cells (EC50 values of 18 and 2.1 nM, respectively), and evoked a dose-dependent activation of TRPV4 whole-cell currents at concentrations above 1 nM. It is 300 fold more potent than 4a-PDD. Applications: A novel and potent trpv4 channel agonist. Group: Coenzymes. Synonyms: (N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide. CAS No. 942206-85-1. Purity: ≥98%. Mole weight: 655.61. Form: Solid. (N-((1S)-1-{[4-((2S)-2-{[(2,4-Dichlorophenyl)sulfonyl]amino}-3-hydroxypropanoyl)-1-piperazinyl]carbonyl}-3-methylbutyl)-1-benzothiophene-2-carboxamide; GSK1016790A; 942206-85-1. Cat No: COEC-115. | |
| GSK1016790A | GSK1016790A is a novel and potent transient receptor potential vanilloid 4 (TRPV4) agonist. It has been used to demonstrate a role for TRPV4 in regulating urinary bladder activity and endothelial control of vascular tone. It elicited Ca2+ influx in mouse and human TRPV4 expressing HEK cells with EC50 values of 18 and 2.1 nM, respectively. It also evoked a dose-dependent activation of TRPV4 whole-cell currents at concentrations above 1 nM, which is 300 fold more potent than 4a-PDD. It was developed by GlaxoSmithKline. Uses: Gsk1016790a regulats urinary bladder activity and endothelial control of vascular tone. Synonyms: GSK1016790A; GSK-1016790A; GSK 1016790A. N-((S)-1-(4-((S)-2-(2,4-dichlorophenylsulfonaMido)-3-hydroxypropanoyl)piperazin-1-yl)-4-Methyl-1-oxopentan-2-yl)benzo[b]thiophene-2-carboxaMide. Grades: >98 %. CAS No. 942206-85-1. Molecular formula: C28H32Cl2N4O6S2. Mole weight: 655.61. | |
| GSK1059615 | GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC 50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 958852-01-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-12036. | |
| GSK1059615 | GSK1059615 is a dual inhibitor of PI3Kα/β/δ/γ (reversible) and mTOR with IC50 of 0.4 nM/0.6 nM/2 nM/5 nM and 12 nM, respectively. Synonyms: GSK-1059615; GSK 1059615; GSK1059615. Grades: >98%. CAS No. 958852-01-2. Molecular formula: C18H11N3O2S. Mole weight: 333.36. | |
| GSK 1059615 | GSK 1059615 is a potent inhibitor of PI 3-kinase α (PI3Kα). GSK 1059615 inhibits proliferation in BT474 cells and attenuates MAPK signaling. Group: Biochemicals. Alternative Names: (5Z)-5-[[4-(4-Pyridinyl)-6-quinolinyl]methylene]-2,4-thiazolidinedione. Grades: Highly Purified. CAS No. 958852-01-2. Pack Sizes: 10mg. US Biological Life Sciences. | Worldwide |
| GSK-1070806 | GSK-1070806 is a CHO-expressed humanized antibody that targets IL-18. GSK-1070806 contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 147.38 kDa. The isotype control for GSK-1070806 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001). Uses: Scientific research. Group: Inhibitory antibodies. Alternative Names: Aletekitug. CAS No. 2923284-67-5. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-P990591. | |
| GSK-1070916 | GSK-1070916 is a potent and selective ATP-competitive inhibitor of aurora B and aurora C with Kis of 0.38 and 1.5 nM, respectively, and is >250- fold selective over Aurora A. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK-1070916A. CAS No. 942918-07-2. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-70044. | |
| GSK-1070916A | GSK-1070916A is an ATP-competitive inhibitor of the serine/threonine kinases Aurora B and C with potential antineoplastic activity. Aurora B/C kinase inhibitor GSK1070916A binds to and inhibits the activity of Aurora kinases B and C, which may result in inhibition of cellular division and a decrease in the proliferation of tumor cells that overexpress the Aurora kinases B and C. Aurora kinases play essential roles in mitotic checkpoint control during mitosis, and are overexpressed by a wide variety of cancer cell types. Synonyms: GSK 1070916; GSK-1070916; GSK 1070916; GSK1070916A; GSK-1070916A; GSK 1070916A; NMI-900; NMI 900; NMI900. CAS No. 942918-07-2. Molecular formula: C30H33N7O. Mole weight: 507.63. | |
| GSK-1071306 | GSK-1071306 is one of the metabolites of pazopanib which is a inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity as a approved drug. Synonyms: GSK-1071306; GSK1071306; GSK 1071306; Pazopanib metabolite M27;5-((4-((2,3-dimethyl-2H-indazol-6-yl)amino)-2-pyrimidinyl)amino)-2-methyl-Benzenesulfonamide. Grades: 98%. CAS No. 1252927-47-1. Molecular formula: C20H21N7O2S. Mole weight: 423.49. | |
| GSK1120212 | JTP-74057. anticancer agent for pancreatic islet cells. CAS No. 871700-17-3. Product ID: 8-04708. Molecular formula: C26H23FIN5O4. Mole weight: 615.39. |  |
| GSK-114 | GSK-114 is a selective TNNI3 Interacting Kinase (TNNI3K) inhibitor with IC50 of 25nM. GSK-114 shows significant bias for TNNI3K over B-Raf, exceptional broad spectrum kinase selectivity and adequate oral exposure to enable its use in cellular and in vivo studies. Ralated studies has shown that TNNI3 Interacting Kinase has been linked to the progression of dilated cardiomyopathy, cardiac hypertrophy, and ischemia/reperfusion injury using models that employ TNNI3K overexpressing or TNNI3K knockout animals. Synonyms: GSK-114; GSK 114; GSK114; 3-((6,7-dimethoxyquinazolin-4-yl)amino)-4-(dimethylamino)-N-methylbenzenesulfonamide; 1301760-19-9 (2HCl). Grades: 98%. CAS No. 1301761-96-5. Molecular formula: C19H23N5O4S. Mole weight: 417.48. | |
| GSK-114 2Hcl | GSK-114 is a potent and selective TNNI3K inhibitor (TNNI3 IC50 = 25nM; B-RafV600E IC50 = 1000 nM). GSK-114 displays significant bias (40-fold) for TNNI3K over B-Raf, exceptional broad spectrum kinase selectivity, and adequate oral exposure to enable its use in cellular and in vivo studies. Synonyms: GSK-114 2Hcl; GSK114 2Hcl; GSK 114 2Hcl. CAS No. 1301760-19-9. Molecular formula: C19H23N5O4S.2HCl. Mole weight: 495.484. | |
| GSK1210151A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK121 trifluoroacetate salt | GSK121 is an inhibitor for protein arginine deiminase 4 (PAD4), which has been shown to inhibit the citrullination of PAD4 target proteins in a functional assay with an IC50 value of 3.2 μM. Synonyms: (3-amino-1-piperidinyl)[1-methyl-2-(1-methyl-1H-indol-2-yl)-1H-benzimidazol-5-yl]-methanone, 2,2,2-trifluoroacetate. Grades: ≥98%. CAS No. 1652591-80-4. Molecular formula: C23H25N5O·CF3COOH. Mole weight: 501.5. | |
| GSK126 | GSK126 is a potent and highly selective S-adenosyl-methionine-competitive small molecule inhibitor of EZH2 methyltransferase enzyme activity. The inhibition activity of GSK126 on EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma. Group: Biochemicals. Alternative Names: N-[(1,2-Dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-3-methyl-1-[(1S)-1-methylpropyl]-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-Indole-4-carboxamide; N-[(4,6-Dimethyl-2-oxo-1,2-dihydro-3-pyridinyl)methyl]-3-methyl-1-((1S)-1-methylpropyl)-6-[6-(1-piperazinyl)-3-pyridinyl]-1H-indole-4-carboxamide. Grades: Highly Purified. CAS No. 1346574-57-9. Pack Sizes: 5mg. US Biological Life Sciences. | Worldwide |
| GSK126 | GSK126 is a potent, highly selective, S-adenosyl-methionine-competitive, small-molecule inhibitor of EZH2 methyltransferase activity. GSK126 decreases global H3K27me3 levels and reactivates silenced PRC2 target genes. GSK126 effectively inhibits the proliferation of EZH2 mutant DLBCL cell lines and markedly inhibits the growth of EZH2 mutant DLBCL xenografts in mice. Together, these data demonstrate that pharmacological inhibition of EZH2 activity may provide a promising treatment for EZH2 mutant lymphoma. Synonyms: GSK2816126; GSK-2816126; GSK 2816126; GSK-126; GSK 126; (S)-1-(sec-Butyl)-N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-3-methyl-6-(6-(piperazin-1-yl)pyridin-3-yl)-1H-indole-4-carboxamide. Grades: 98%. CAS No. 1346574-57-9. Molecular formula: C31H38N6O2. Mole weight: 526.69. | |
| GSK126 | GSK126 (GSK2816126A) is a potent, highly selective inhibitor of EZH2 methyltransferase with an IC50 of 9.9 nM[1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: GSK2816126A. CAS No. 1346574-57-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg. Product ID: HY-13470. | |
| GSK126 | GSK126 Inhibitor. Uses: Scientific use. Product Category: T2079. CAS No. 1346574-57-9. |  |
| GSK-1268992 | GSK-1268992 is one of a metabolite of Pazopanib which is a selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. Synonyms: GSK-1268992; GSK1268992; GSK 1268992; Pazopanib metabolite M24;5-((4-((3-(Hydroxymethyl)-2-methyl-indazol-6-yl)-methyl-amino)pyrimidin-2-yl)amino)-2-methyl-benzenesulfonamide. Grades: 98%. CAS No. 1414375-49-7. Molecular formula: C21H23N7O3S. Mole weight: 453.52. | |
| GSK-1268997 | GSK-1268997 is one of a metabolite of Pazopanib which is a selective multi-targeted receptor tyrosine kinase inhibitor that blocks tumour growth and inhibits angiogenesis. Synonyms: GSK-1268997; GSK1268997; GSK 1268997; Pazopanib metabolite M26; 5-((4-((2,3-Dimethylindazol-6-yl)-methyl-amino)pyrimidin-2-yl)amino)-2-(hydroxymethyl)benzenesulfonamide. Grades: 98%. CAS No. 1414375-50-0. Molecular formula: C21H23N7O3S. Mole weight: 453.52. | |
| GSK-1292263 | GSK1292263 is a novel GPR119 receptor agonist used for the treatment of type 2 diabetes. Synonyms: GSK1292263; GSK 1292263l; GSK-1292263. Grades: 0.98. CAS No. 1032823-75-8. Molecular formula: C23H28N4O4S. Mole weight: 456.561. | |
| GSK1324726A | GSK1324726A is a novel, potent and selective small molecule inhibitor of BET proteins with high affinity to BRD2 (IC50 = 41 nM), BRD3 (IC50 = 31 nM), and BRD4 (IC50 = 22 nM). Synonyms: I-BET-726; I-BET 726; I-BET726; GSK-1324726A; GSK 1324726A. Grades: >98%. CAS No. 1300031-52-0. Molecular formula: C25H23ClN2O3. Mole weight: 434.91. | |
| GSK1324726A | GSK1324726A Inhibitor. Uses: Scientific use. Product Category: T6021. CAS No. 1300031-52-0. | |
| GSK1324726A (I-BET726) | Cas No. 1300031-52-0. | |
| GSK137647A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK137647A | GSK137647A, a diarylsulfonamide, is an agonist of the free fatty acid receptor 4 [GPR120 (pEC50s = 6.3, 6.2, and 6.1 at human, mouse, and rat receptors, respectively)]. Uses: A selective ffa4 agonist. Synonyms: GSK137647A; GSK-137647A; GSK 137647A; GSK137647; GSK-137647; GSK 137647; 4-methoxy-N-(2,4,6-trimethylphenyl)-benzenesulfonamide. Grades: ≥98%. CAS No. 349085-82-1. Molecular formula: C16H19NO3S. Mole weight: 305.4. | |
| GSK143 | GSK143 is a selective SYK inhibitor, which abrogates survival signals in chronic lymphocytic leukaemia. Synonyms: 2-{[(3r,4r)-3-Aminotetrahydro-2h-Pyran-4-Yl]amino}-4-[(4-Methylphenyl)amino]pyrimidine-5-Carboxamide. CAS No. 1240390-27-5. Molecular formula: C17H22N6O2. Mole weight: 342.40. | |
| GSK 143 dihydrochloride | | |
| GSK-1440115 | GSK-1440115 is an orally active urotensin II receptor antagonist. It is used for the treatment of asthma. Uses: Gsk-1440115 is used for the treatment of asthma. Synonyms: GSK 1440115; GSK-1440115; GSK1440115. 4'-(1-(((6,7-Dichloro-3-oxo-2,3-dihydro-4H-1,4-benzoxazin-4-yl)acetyl)(methyl)amino)-2-(4-morpholinyl)ethyl)-4-diphenylcarboxylic acid;4-[4-[(1R)-1-[[2-(6,7-dichloro-3-oxo-1,4-benzoxazin-4-yl)acetyl]-methylamino]-2-morpholin-4-ylethyl]phenyl]benzoic acid. Grades: >98 %. CAS No. 1003878-16-7. Molecular formula: C30H29Cl2N3O6. Mole weight: 598.47. | |
| GSK-1482160 | GSK-1482160 is an orally available negative allosteric modulator of the P2X7 receptor. P2X7 receptors are involved in the production of pro-inflammatory cytokines, such as Il-1?, by central and peripheral immune cells. GSK-1482160 has the potential for the research of inflammation diseases[1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1001389-72-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-19888. | |
| GSK1521498 | GSK-1521498 is a novel μ-Opioid receptor antagonist. It shows to attenuate reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating in animals and humans. It is mainly used for the treatment of obesity and alcohol dependence. It was developed by GlaxoSmithKline and in clinic phase 2. Uses: Gsk-1521498 is mainly used for the treatment of obesity and alcohol dependence. Synonyms: GSK-1521498; GSK1521498; GSK 1521498; GSK-1521498B;N-[[2,6-difluoro-4-[3-(1H-1,2,4-triazol-5-yl)phenyl]phenyl]methyl]-2,3-dihydro-1H-inden-2-amine;N-((3,5-difluoro-3'-(1H-1,2,4-triazol-3-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,3-dihydro-1H-inden-2-amine. Grades: >98 %. CAS No. 1007573-18-3. Molecular formula: C24H20F2N4. Mole weight: 402.44. | |
| GSK1521498 free base | GSK1521498 free base is a potent and selective μ-opioid receptor (MOR) antagonist. GSK1521498 free base has the potential for disorders of compulsive consumption of food, alcohol, and agents [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1007573-18-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-115066. | |
| GSK 1562590 hydrochloride | GSK 1562590 hydrochloride is a high affinity and selective antagonist of urotensin-II receptor (UT) , with pK i s of 9.14-9.66 for mammalian recombinant (mouse, rat, cat, monkey, human) and native UT [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 1003878-07-6. Pack Sizes: 1 mg; 5 mg; 10 mg; 50 mg. Product ID: HY-108446. | |
| GSK 1562590 hydrochloride | GSK 1562590 hydrochloride is a high affinity and selective urotensin II (UT) receptor antagonist (pKi = 9.14, 9.28, 9.34, 9.64 and 9.66 at monkey, human, mouse, cat and rat recombinant receptors, respectively). It displays selectivity for UT receptors over a range of GPCRs, ion channels, enzymes and neurotransmitter transporters. GSK 1562590 has been shown to inhibit human urotensin-II (hU-II)-induced contraction of isolated rat aorta in vitro and ex vivo. Synonyms: GSK 1562590 hydrochloride; GSK1562590 hydrochloride; GSK-1562590 hydrochloride; N-[(1R)-1-[3'-(Aminocarbonyl)[1,1'-biphenyl]-4-yl]-2-(1-pyrrolidinyl)ethyl]-6,7-dichloro-2,3-dihydro-N-methyl-3-oxo-4H-1,4-benzoxazine-4-acetamide hydrochloride; 3-[4-[(1R)-1-[[2-(6,7-dichloro-3-oxo-1,4-benzoxazin-4-yl)acetyl]-methylamino]-2-pyrrolidin-1-ylethyl]phenyl]benzamide hydrochloride. Grades: ≥98% by HPLC. CAS No. 1003878-07-6. Molecular formula: C30H30Cl2N4O4.HCl. Mole weight: 617.95. | |
| GSK163090 | GSK163090 is Potent, selective, and orally active 5-HT1A/B/D receptor antagonist. Synonyms: 1-(3-(2-(4-(2-methylquinolin-5-yl)piperazin-1-yl)ethyl)phenyl)imidazolidin-2-one; GSK163090; GSK-163090; GSK 163090. Grades: 98%. CAS No. 844903-58-8. Molecular formula: C25H29N5O. Mole weight: 415.54. | |
| GSK1702934A | GSK1702934A is a selective TRPC3 agonist. GSK1702934A modulates cardiac contractility and f arrhythmogenesis by activation of TRPC3[1][2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 924377-85-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-111098. | |
| GSK1702934A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK 1702934A | GSK 1702934A is a potent and selective TRPC3/6 activator (EC50 = 80 and 440 nM for TRPC3 and 6, respectively). However, it exhibits no activity at TRPV4, TRPA1, M1, M4, CaV1.2, hERG, NaV1.5, or CXCR5 receptors at concentrations <10 μM. Synonyms: 1,3-Dihydro-1-[1-[(5,6,7,8-tetrahydro-4H-cyclohepta[b]thien-2-yl)carbonyl]-4-piperidinyl]-2H-benzimidazol-2-one; 3-[1-(5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-2-carbonyl)piperidin-4-yl]-1H-benzimidazol-2-one; GSK-2934A. Grades: ≥98% by HPLC. CAS No. 924377-85-5. Molecular formula: C22H25N3O2S. Mole weight: 395.52. | |
| GSK172981 | This molecular is a novel non-peptide tachykinin NK3 receptor antagonist and it has a very high affinity for native guinea pig (pK(I) value 7.8) tachykinin NK(3) receptors and recombinant human (pK(I) value 7.7). Meanwhile, GSK172981 also exhibited a competitive profile in antagonizing neurokinin B-stimulated neuronal activity recorded from the guinea pig medial habenula slices (apparent pK(B)=8.1). In the near future, this active molecular may be promising drug candidate in the treatment of schizophrenia. Uses: Treatment of schizophrenia. Synonyms: GSK172981; GSK-172981; GSK 172981. (S)-3-amino-N-(cyclopropyl(phenyl)methyl)-2-(3-fluorophenyl)quinoline-4-carboxamide. Grades: 98%. CAS No. 1133705-99-3. Molecular formula: C26H22FN3O. Mole weight: 411.48. | |
| GSK180736A | GSK180736A is a potent and selective inhibitor of GRK2 (IC50 = 0.77 μM) and ROCK1 (IC50 = 14 nM). Synonyms: GSK-180736A; 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-3,4-dihydro-1H-pyrimidine-5-carboxamide. Grades: >98%. CAS No. 817194-38-0. Molecular formula: C19H16FN5O2. Mole weight: 365.37. | |
| GSK180736A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK1838705A | ?98% (HPLC). Group: Fluorescence/luminescence spectroscopy. | |
| GSK1838705A | GSK1838705A is a small-molecule kinase inhibitor that inhibits IGF-IR and IR (insulin receptor) with IC50s of 2.0 and 1.6 nM, respectively. GSK1838705A blocks the in vitro proliferation of cell lines derived from solid and hematologic malignancies, including multiple myeloma and Ewing's sarcoma, and retards the growth of human tumor xenografts in vivo. Despite the inhibitory effect of GSK1838705A on insulin receptor, minimal effects on glucose homeostasis were observed at efficacious doses. GSK1838705A also inhibits the anaplastic lymphoma kinase (ALK), which drives the aberrant growth of anaplastic large-cell lymphomas, some neuroblastomas, and a subset of non-small cell lung cancers. GSK1838705A inhibits ALK, with an IC(50) of 0.5 nmol/L, and causes complete regression of ALK-dependent tumors in vivo at well-tolerated doses. GSK1838705A is therefore a promising antitumor agent for therapeutic use in human cancers. Synonyms: GSK1838705A; GSK-1838705A; GSK-1838705A. Grades: 0.98. CAS No. 1116235-97-2. Molecular formula: C27H29FN8O3. Mole weight: 532.57. | |
| GSK1842799 | GSK1842799 is a selective S1P1 receptor agonist for multiple sclerosis. It showed subnanomole S1P1 agonist activity with >1000× selectivity over S1P3 upon phosphorylation. It has good oral bioavailability. It was selected as a candidate for further clinical on the basis of the favorable in vitro ADME and in vivo PK/PD properties as well as broad toxicology evaluations. Uses: Gsk1842799 was selected as a candidate for further clinical. Synonyms: (S)-2-amino-2-(5-(4-(octyloxy)-3-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)propan-1-ol;GSK1842799; GSK 1842799; GSK 1842799. Grades: >98 %. CAS No. 1005407-76-0. Molecular formula: C20H28F3N3O2S. Mole weight: 431.52. | |
Our database is helping our users find suppliers everyday.
